Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
14 Ottobre 2008 - 1:30PM
PR Newswire (US)
Also debuts TMR'09 campaign IRVINE, Calif., Oct. 14
/PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets:
CGCP), a global leader of innovative therapies for ischemic cardiac
disease and the market leader of surgical products for
transmyocardial revascularization (TMR), sponsored an educational
symposium yesterday in conjunction with the 20th Annual
Transcatheter Cardiovascular Therapeutics (TCT) meeting in
Washington, D.C. The symposium, titled "New Horizons in Cardiac
Regenerative Medicine: Advancements in Revascularization & Stem
Cell Therapy," was attended by over 120 cardiology healthcare
practitioners. The Program Chair was Warren Sherman, MD, Director
of Cardiac Cell Based Endovascular Therapies, Center for
Interventional Vascular Therapy, New York-Presbyterian
Hospital/Columbia University Medical Center. Presenters included:
Emerson Perin, MD, PhD, Director, New Interventional Cardiovascular
Technology, Texas Heart Institute; Marvin Slepian, MD, Director of
Interventional Cardiology, University of Arizona, Sarver Heart
Center; and Keith Allen, Cardiothoracic Surgeon, Mid America Heart
and Thoracic surgeons, Kansas City, MO. "The program was designed
to provide an update to clinicians on the recent developments with
advanced cardiovascular revascularization and regenerative
therapies, with a focus on patients suffering from ischemic cardiac
disease," Dr. Sherman stated. "TCT attendees are eager to learn
about rapidly evolving therapies, as well as the latest information
on optimizing outcomes with available tools and techniques,
including TMR as a sole therapy and adjunctive to bypass surgery."
Dr. Allen emphasized to the cardiologists in attendance, "Surgeons
are innovating with Cardiogenesis to provide TMR with minimally
invasive approaches, including surgical robotic delivery." He also
discussed the early clinical experience with the PHOENIX
combination delivery system being collected from centers outside
the U.S. As a leading clinical investigator of autologous stem cell
trials, Dr. Perin provided a state of the art overview of
cardiovascular stem cell clinical trials. He concluded, "The
tissue-stimulated zone generated by TMR, along with the precise
delivery of stem cells, may prove to be more potent in combination
than either therapy alone." TMR'09 campaign assists in ID of
patients that TMR can help "We understand the trust and respect
with which a heart patient views recommendations and treatment
options from his or her cardiologist," said Richard Lanigan,
President of Cardiogenesis. "A focus of our TMR'09 campaign is to
provide cardiologists with the latest information on the clinical
utility of TMR and to assist them in identifying and educating
patients who can benefit. We will build on this event in driving
the awareness of the benefits of TMR with cardiologists and
patients, as well as the advantages provided with our minimally
invasive PEARL delivery systems." About Cardiogenesis Corporation
Cardiogenesis is a global leader in providing new and innovative
therapeutic solutions for ischemic cardiac disease. The company's
market leading Holmium:YAG laser system and disposable fiber-optic
accessories are used to perform an FDA-cleared surgical procedure
known as Transmyocardial Revascularization (TMR) to treat patients
suffering from angina. Surgical products and accessories for the
Cardiogenesis TMR procedure, which are marketed in the U.S. and
around the world, have been shown to reduce angina and improve the
quality of life in patients with coronary artery disease. For more
information on the company and its products, please visit the
Cardiogenesis company website at http://www.cardiogenesis.com/ or
the direct to patient website at http://www.heartofnewlife.com/.
With the exception of historical information, the statements set
forth above include forward-looking statements. Any forward-looking
statements in this news release related to the possible
effectiveness of the company's PHOENIX delivery system or other
technologies and the effect of such system or technology on the
company's sales, profitability, the adoption of its technology and
products and FDA clearances are based on current expectations and
beliefs and are subject to numerous risks and uncertainties, many
of which are outside the company's control, that could cause actual
results to differ materially. Factors that could affect the
accuracy of these forward-looking statements include, but are not
limited to: any inability by the company to sustain profitable
operations or obtain additional financing on favorable terms if and
when needed; any failure to obtain required regulatory approvals;
failure of the medical community to expand its acceptance of TMR or
PMC procedures; possible adverse governmental rulings or
regulations, including any FDA regulations or rulings; the
company's ability to comply with international and domestic
regulatory requirements; possible adverse Medicare or other
third-party reimbursement policies or adverse changes in those
policies; any inability by the company to ship product on a timely
basis; the company's ability to manage its growth; adverse economic
developments that could adversely affect the market for our
products or our ability to raise needed financing; actions by our
competitors; restrictions contained in our convertible debt
obligations requiring the issuance of shares rather than repayment
in cash; and the company's ability to protect its intellectual
property. Other factors that could cause Cardiogenesis' actual
results to differ materially are discussed in the "Risk Factors"
section of the company's Annual Report on Form 10-KSB for the year
ended December 31, 2007 and the company's other recent SEC filings.
The company disclaims any obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release. DATASOURCE: Cardiogenesis Corporation CONTACT:
William R. Abbott, Senior Vice President and Chief Financial
Officer of Cardiogenesis Corporation, +1-949-420-1800 Web site:
http://www.cardiogenesis.com/ http://www.heartofnewlife.com/
Copyright